Sezgin TOPUZ

Immune status of splenectomized patients following vaccination against encapsulated bacteria

Aim: The current study aimed to observe the effectiveness of a pneumococcal vaccine and a Haemophilus influenzae vaccine insplenectomized patients by quantification of serum antibody and complement levels, analysis of T and B lymphocytes with flowcytometry and determination of the percentage of Natural Killer cells and the CD4+ to the CD8+ lymphocyte ratio.Material and Methods: The study included 22 adult patients who had undergone splenectomy between May 1999 and December2006. The Pneumo-23 vaccine was administered for protection against Streptococcus pneumonia to all patients, whereas the Act-HIBvaccine was administered for protection against Haemophilus influenzae type B to 12 patients after January 2002.Hemogram, IgG and IgM antibody concentrations, serum levels of Complement protein 3 and Complement Protein 4 were obtainedand lymphocytes were analyzed whether they were CD3+ and CD19+ by flow cytometry. At the second time point, in 2009, CD4+/CD8+T-cell ratio and the percentage of CD3/CD16+CD56 Natural Killer cells were evaluated in addition to aforementioned parameters.Results: All of the study patients had normal IgG levels. Three patients had low levels of IgM. C3 and C4 values were normal. Tenpatients showed a low CD3+ T-cell distribution at 5 years. The percentage of CD19+ B-lymphocytes returned to normal. Sustainedsuppression of CD19 level was observed only in one patient with immune thrombocytopenic purpura. CD8 distribution was normalin all patients. At 5 years, reduced CD4 percentage was detected in 5 patients with immune thrombocytopenic purpura, 3 of whomhad suppressed levels of Natural Killer cells concomitantly. Normal levels of IgG, C3, C4 and CD19+ B-cell percentages were foundat the final laboratory assessment for all patients.Conclusion: Our findings indicate that immunological functions are restored following administration of the Pneumo-23 and ActHIB vaccines. Further studies are needed to obtain a prognostic immune profile index that could help predict patients at high risk forpost-splenectomy sepsis.

PDF

___

1. Schwartz SI. Role of splenectomy in hematologic disorders. World J Surg.1996;20:1159.
2. Evans D. Postsplenectomy sepsis ten years or more after operation. J Clin Pathol 1985;38: 309-11.
3. Dawson AA, Jones PF, King DJ. Splenectomy in the management of hematological disease. Br J Surg 1987;74:353-7.
4. Yusuke H, Toshiro O, Tetsuro S , et al. Immunological consequences following splenectomy in patients with liver cirrhosis. Exp Ther Med 2019;18:848-56.
5. Rubins J, Alter M, Loch J, et al. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999;67:5979-84.
6. Farr B, Johnston B, Cobb DK, et al. Preventing pneumococcal bacteriemia in patients at risk. Results of a matched case-control study. Arch Intern Med 1995;155:2336-40.
7. Käyhty H, Åhman H, Rönnberg PR, et al. Pneumococcal polysaccharide–meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children. J Infect Dis 1995;172:1273-8.
8. Sigurdardottir ST, Vidarsson G, Gudnason T, et al. Immune responses of infants vaccinated with serotype 6B pneumococcal polysaccharide conjugated with tetanus toxoid. Pediatr Infect Dis J 1997;16:667-74.
9. Romaro-Steiner S, Libutti D, Pais L, et al. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using HL-60 cells. Clin Diagn Lab Immunol 1997;4:415-22.
10. Nieminen T, Käyhty H, Virolainen A, et al.Circulating antibody secreting cell response to parenteral pneumococcal vaccines as an indicator of a salivary IgA antibody response. Vaccine 1998;16:313-9.
11. Chadburn A. The spleen: Anatomy and anatomical function. Semin Hematol 2000;37:13-21.
12. Vidarsson G, Sigurdardottir S, Gudnason T, et al. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine. Infect Immun 1998;66:2866-70.
13. Wilkins WB. Historical Review. Br J Haematol 2002; 117:265.
14. Vidarsson G, van de Winkel J. Fc receptor and complement receptor-mediated phagocytosis in host defence. Curr Opin Infect Dis 1998;11:271-8.
15. Ruben FL, Hankins WA, Zeigler Z, et al. Antibody responses to meningococcal polysaccharide vaccine in adults without a spleen. Am J Med 1984;76:115-21.
16. Dawson AA, Jones PF, King DJ. Splenectomy in the management of hematological disease. Br J Surg 1987;74:353-7.
17. Landgren O, Bjorkholm M, Konradsen HB, et al. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin’s lymphoma. J Internal Med 2004;255:664-73
18. Davies JM, Barnes R, Milligan D. British Committee for Standards in Haematology. Working Party of the Haematology/Oncology Task Force. Update of guidelines for the prevention and treatment of infection in patients with an absentor dysfunctional spleen. Clin Med 2002;2:440-3.
19. Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998;10:252-8.